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Abstract:  Chelation therapy is the preferred  medical treatment  for  reducing  the toxic 
effects of metals. Chelating agents are capable of binding to toxic metal ions to form 
complex structures which are  easily excreted from the body  removing them from 
intracellular or extracellular spaces.  2,3-Dimercaprol has long been the mainstay of 
chelation therapy for lead or arsenic poisoning, however its serious side effects have led 
researchers to develop less toxic analogues.  Hydrophilic chelators like meso-2,3-
dimercaptosuccinic acid effectively promote renal metal excretion, but their ability to 
access  intracellular  metals  is weak.  Newer strategies to address these drawbacks like 
combination therapy (use of structurally different chelating agents) or co-administration of 
antioxidants  have been reported recently. In  this  review  we provide an  update of the 
existing chelating agents and the various strategies available for the treatment of heavy 
metals and metalloid intoxications.  
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1. Introduction 
 
Metals are an integral part of many structural and functional components in the body, and the 
critical role of metals in physiological and pathological processes has always been of interest to 
researchers. Unfolding the latter has inspired newer therapeutic strategies based on alteration of the 
metal concentrations in specific body organs and/or entire body evolving branches like 
metallotoxicology and metallopharmacology. The use of metals to restore the normal healthy 
physiology of the body either by direct administration of essential metals, or by chelating out excess or 
toxic metals, or using them as carriers for targeted drug delivery, or for tagging biomolecules for 
diagnostics,  are all  techniques that may be classified under the general  heading  of  
metallo-pharmacology. However, in the present review we will restrict our discussion to chelation 
therapy which is an important concept and tool for modifying metal concentrations  in the body. 
Chelation has its origin in the Greek word chele that means claw of a lobster, thus depicting the 
concept of clinging or holding with a strong grip. The term chelate was first applied by Sir Gilbert T. 
Morgan and H. D. K. Drew in 1920.  They  suggested  the  term  for the caliper-like groups which 
function as two associating units and fasten to a central atom so as to produce heterocyclic rings [1].  
Metal toxicity may occur due to essential metal overload or exposure to heavy metals from various 
sources. Most metals are capable of forming covalent bonds with carbon, resulting in metal-organic 
compounds. Metals and metal compounds interfere with functions of various organ systems like the 
central nervous system (CNS), the haematopoietic system, liver, kidneys, etc. Diagnostic testing for 
the presence of heavy metals, and subsequently decreasing the body’s burden of these substances, 
should be an integral part of the overall treatment regimen for individuals with a metal poisoning 
symptomatology or a known exposure to these substances. 
 
2. Chelation: Concept and Chemistry 
 
Although the concept of chelation is based on simple coordination chemistry, evolution of an ideal 
chelator and chelation therapy that completely removes specific toxic metal from desired site in the 
body  involves  an  integrated  drug design approach.  Chelating agents are organic or inorganic 
compounds capable of binding  metal ions to form complex  ring-like structure called ‘chelates’. 
Chelating agents possess  “ligand” binding atoms that form  either  two covalent linkages  or  one 
covalent and one co-ordinate or two co-ordinate linkages in the case of bidentate chelates. Mainly 
atoms like S, N and O function as ligand atoms in the form of chemical groups like –SH, –S-S, –NH2, 
=NH, –OH, –OPO3H, or >C=O. Bidenate or multidentate ligands form ring structures that include the 
metal ion and the two-ligand atoms attached to the metal [2] (Figure 1). Many donors act as bidentate 
ligands. Five-membered chelate rings are specially stable and they are often formed by ligands with 
YCCY skeltons such as Y-CH2-CH2-Y, Y-CO-CH2-Y etc. where Y is OR, NR2, O, S, NR, etc. There 
are also examples of inorganic chelate ligands which form five-membered ring with metal ions. Other 
types of chelating ligands are possible, like EDTA
4−, which is a hexadentate ligand. In the simplest 
case a proton (H
+) that can absorb the lone pair of electrons of ligand-binding atom(s) of the chelator 
may be involved in the coordination complex formation. However, the positive charge on proton 
remains since there is no loss or gain of electrons in the process.  Int. J. Environ. Res. Public Health 2010, 7                 
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Figure 1. Formation of metal ligand complexes using mono, bi and polydentate ligands. 
 
 
The latter may also be known as the ‘net ionic charge’ of the complex, which plays a crucial role in 
governing the pharmacokinetic fate and ultimately the toxicological behavior of such complexes in 
vivo. In the biological environment metal cations viz. Na
+, Mg
+, Cu
+, Cu
2+, and Zn
2+ and specially the 
transition metals like Mn, Fe and Co may be involved in such  complex formation. Although the 
stability of such complexes varies,  the deciding factors are based on the properties of both the 
chelating agent and the chelated metal. The stability constant of a complex  can be quantitatively 
expressed in equilibrium equation values, which depend on the atomic structure of the chelated metals. 
For example, the stability constants for different metals with EDTA are on the scale shown in Table 1, 
where a metal with higher k constant competes for the chelating agent with a metal of lower stability 
value and ultimately removes the latter.  
 
Table 1. EDTA-metal complex stability constants. 
Metal  Na  Li  Ba  Sr  Mg  Ca  Mn  Fe  Co  Zn  Cd  Pb  Ni 
K (log)  1.7  2.8  7.8  8.6  8.7  10.6  13.4  14.4  16.1  16.1  16.4  18.3  18.4 
 
However, other variables like the number of heterocyclic rings formed and relative concentration 
also play a role, that’s why Ca
2+,
 which is readily available in the body fluids, binds preferentially with 
Na2EDTA in spite of the higher stability constant of Pb. Moreover, in spite of all the known properties 
desired in an ideal chelator the predictability of the outcome is limited. A chemical entity that qualifies 
as an ideal chelator in vitro might not prove so in vivo, either due to the toxicity considerations or due 
to the presence of endogenous substances (hemoglobin, cytochromes, etc.) that can also chelate metal 
ions and thus offer competition.  Int. J. Environ. Res. Public Health 2010, 7                 
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Further, pH also is an important factor influencing complex formation and stability. Most chelating 
agents are unstable at low pH, whereas at high pH metals tend to form insoluble hydroxides which are 
less accessible to chelating agents. This feature becomes significant in pathological conditions leading 
to acidosis or alkalosis.  
Optimally effective chelation can be achieved by virtue of some combination of the basic properties 
of both the metal ions, chelating agents and the resulting metal complex. A chelating agent that will 
occupy more of the coordination positions of a metal ion will generally (but not always) give a 
complex of greater stability than otherwise. Similarly, whereas the net ionic charge of the chelator 
defines its absorption, distribution and ability to reach the metal ion for binding; the net ionic charge of 
the complex decides its elimination from the specific site and excretion from the body. Thus, it is 
important that a chelator satisfy criteria that allow it to: (1) transport across physiological barriers into 
compartments where a toxic metal ion is concentrated, (2) form a stable complex with the metal after 
removing it from the biological chelator, if required at the site and (3) form a chelation complex whose 
properties render it non-toxic and facilitate its excretion, not only from the site of deposition, but also 
from the body [3].  
 
3. Common Chelating Agents: Pharmacology and Toxicology 
 
An ideal chelator should have high solubility in water, resistance to biotransformation, ability to 
reach the sites of metal storage, retain chelating ability at the pH of body fluids and the property of 
forming metal complexes that are less toxic than the free metal ion (Figure 2).  
Figure 2. Characteristics of an ideal chelating agent for better chelation of heavy metals. 
 
During Second World War, dimercaprol (also named British Anti-Lewisite or BAL), an organic 
dithiol compound, was developed as an experimental antidote against the arsenic-based poison gas 
Lewisite. After World War II, mass lead poisoning was observed in large number of navy personnel, 
later identified as a result of their jobs repainting the hulls of ships. This introduced the medical use of 
Characteristics of an Ideal Chelator 
• Greater Affinity, Low Toxicity 
•Ability to compete with natural chelators 
•Ability to penetrate cell membranes 
•Rapid elimination of the toxic metal 
•High water solubility 
•Capacity to form non-toxic complexes 
•Same distribution as the metal Int. J. Environ. Res. Public Health 2010, 7                 
 
2749 
EDTA as a lead chelating agent. BAL has dominated medical prescriptions for general metal 
intoxication due to its high efficacy for human arsenic and mercury poisoning. In the 1960s, BAL was 
modified into meso 2,3-dimercaptosuccinic acid (DMSA), a related dithiol with far fewer side effects. 
Another dithiol, sodium 2,3-dimercaptopropane 1-sulfonate (DMPS), was introduced as a mercury-
chelating agent by researchers in the former Soviet Union. Chelation therapy has historically been used 
in attempts to reduce the body burden of toxic metals in highly symptomatic patients with elevated 
biological markers [4-6]. Chelating agents can affect metal toxicity by mobilizing the toxic metal 
mainly into urine. A chelating agent forming a stable complex with a toxic metal may shield biological 
targets from the metal ion, thereby reducing the local toxicity [7] (Figure 3). Desferrioxamine (DFOA), 
an iron chelator, completely covers the surface of Fe
3+ during complex formation, thereby preventing 
iron-catalyzed free radical reactions [8]. However, sometimes a chelator may expose the metal to the 
biological environment and thus  increase the toxicity of the metal (Figure 3). Ethylenediamine-
tetraacetic acid (EDTA) is not able to shield the surface of the Fe
3+ ion, but forms an open complex 
(basket complex), thereby increasing the catalytic capacity of Fe
3+ for generating oxidative stress [9]. 
Structures of various chelating agents are presented in Figure 4. 
Figure 3. Structures of two different complexes of metals with chelating agents. (A) Stable 
complex prevent interaction of metal with bio-molecules, (B) Basket complex enhance 
interaction of metal with bio-molecules. Symbols used: B- Bio-molecules; C-Chelating 
agent; M- Metal. 
 
 
Preferred ligands for soft and borderline ions such as Pb
2+, Hg
2+, Cd
2+ and As
3+ are thiolates and 
amines. Consequently, known metal-binding sites in most cases contain Cys or His residues. Many of 
these sites consist of contiguous short stretches of amino acid sequences that overlap between 
neighboring peptides with binding activity which are used to tentatively determine major binding 
motifs. The majority of proteins and peptides that function in the uptake, distribution, storage or 
detoxification of essential and non-essential metal ions possess one or several metal-binding sites. The 
M 
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-Cys-X-X-Cys- and -Cys-Cys- motifs of various proteins are well known for their heavy metal binding 
properties [10,11]. It has long been acknowledged that sulfhydryl-containing compounds have the 
ability to chelate metals. The sulfur-containing amino acids methionine and cysteine, N-acetylcysteine, 
an acetylated analogue of cysteine, the methionine metabolite S-adenosylmethionine, α-lipoic acid, and 
the tripeptide glutathione (GSH) all contribute to the chelation and excretion of metals from the   
human body. 
Figure 4.  Structures of various chelating agents used to treat cases of heavy   
metal poisoning. 
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3.1. Calcium Disodium Ethylenediamine Tetraacetic Acid (CaNa2EDTA)  
 
Calcium  disodium ethylenediamine tetraacetic acid (CaNa2EDTA) is the most commonly used 
chelating agent. It is a derivative of ethylenediamine tetraacetic acid (EDTA); a synthetic   
polyamino-polycarboxylic acid and since 1950s has been one of the mainstays for the treatment of 
childhood lead poisoning [12]. The drug has been claimed beneficial in vascular disease since 1955. It 
is believed that chelation therapy may alter plaque morphology and volume, or improve endothelial 
function, and suggest that it might replace coronary artery bypass draft surgery [13]. Several theories 
have been proposed to support latter mainly focusing on calcium chelation. EDTA is said to work in 
vascular conditions either by removing calcium found in fatty plaques either directly via chelation 
effect or alternately by stimulating release of hormones that in turn cause calcium removal or lower 
cholesterol levels. Another theory suggests that EDTA therapy may reduce the oxidative stress injury 
and inflammation in blood vessel walls [14].  
Although a number of trials conducted indicate the utility of CaNa2EDTA in coronary heart disease, 
the evidence in the absence of the controlled trial is not as convincing. In view of reports where 
symptomatic improvements have been comparable with placebo effects and the risks associated with 
the therapy, it has been facing criticism [15]. The American Heart Association has stated that “there 
have been no adequate, controlled, published scientific studies using currently approved scientific 
methodology to support this therapy for coronary heart disease. Using this form of unproven treatment 
for coronary heart disease may deprive patients of the well-established benefits from the many other 
valuable methods of treating these diseases” [13,16] for the program to assess alternative treatment 
strategies to achieve cardiac health (PATCH) investigators also concluded after a randomized control 
trial with 84 patient that there is no evidence to support a beneficial effect of calcium chelation therapy 
with EDTA in patients with ischemic heart disease, stable angina and a positive treadmill test for 
ischemia. Another sub-study under PATCH rejects the proposed benefits of EDTA in combination 
with vitamins to improve impaired endothelium-dependent brachial artery flow-mediated vasodilation 
in patients with coronary artery disease [17]. But recently all randomized clinical trials have been 
underpowered and the NCCAM and the National Heart, Lung, and Blood Institute launched the Trial 
to Assess Chelation Therapy (TACT). TACT is the first largest, multicenter study to assess safety and 
efficacy of EDTA chelation therapy for patients with coronary artery disease. This placebo-controlled, 
double-blind trial has started recruiting participants, aiming at 2,372 sample size, aged ≥ 50 years with 
prior myocardial infarction to test whether EDTA chelation therapy, high dose vitamin therapy, or both 
are effective in secondary prevention. The study started in 2003 and was expected to complete in 5  
years [14]. However, trials are ongoing and conclusive results are not expected before June 2012.  
CaNa2EDTA can be valuable for the treatment of poisoning by metals that have higher affinity for 
chelating agent than does Ca
2+. The successful use of CaNa2EDTA in the treatment of lead poisoning 
is due, in part, to the capacity of lead to displace calcium from the chelate. Initially EDTA was 
introduced as its sodium salt (NaEDTA) which when administered in vivo resulted in the urinary 
excretion of calcium leading to hypocalcaemia with the risk of tetany due to the formation of its 
calcium complex. To overcome this hazard, CaNa2EDTA was introduced for the treatment of lead 
poisoning. The Pb-EDTA complex has high stability constant thus CaNa2EDTA was found to chelate 
lead from the body fluids, excreting PbNa2EDTA leaving Ca behind. Int. J. Environ. Res. Public Health 2010, 7                 
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Pharmacological Profile 
 
CaNa2EDTA is poorly absorbed in the gastrointestinal tract (<5%) thus can only be administered by 
parenteral route. Intravenous administration of this drug results in good absorption but is very painful 
at the injection site. Hence intravenous injection could be given either by diluting in 5% dextrose or 
saline (iv infusion) [12]. CaNa2EDTA is distributed mainly in the extracellular fluids, which limits its 
capacity to chelate out metals from inside the cells. The latter also contributes to one of its major 
drawbacks that  of  redistributing  lead  from other tissues to the brain. Reporting the same,  
Flora et al. [18] recommended avoiding the use of CaNa2EDTA for lead mobilization tests in children. 
It  was suggested that CaNa2EDTA when administered in animals chronically exposed to lead, 
mobilizes the metal deposited in hard tissue for chelation. This then allows mobilized circulating lead 
to redistribute in soft tissues like the brain and liver in order to achieve equilibrium. CaNa2EDTA is 
not significantly metabolized and is excreted rapidly by glomerular filtration, entirely unchanged in 
urine, 50% of which appears within one hour [2]. The drug shows an elimination half life of 1.4 to 3 
hours in adult and is entirely excreted within 24 hours.  
 The risks associated with CaNa2EDTA therapy are substantial,  including renal failures, 
arrhythmias, tetany, hypocalcaemia, hypotension, bone marrow depression, prolonged bleeding time, 
convulsions, respiratory arrest,  etc.  [16].  Although the nephrotoxicity by CaNa2EDTA is dose 
dependent and reversible after cessation of therapy yet exceeding maximal daily dose of 75 mg/kg 
could be fatal. However, there also are reports that highlight the efficacy of EDTA in chronic renal 
artery diseases [19,20]. Other adverse effects may include fatigue, headache, fever, nasal congestion, 
lacrimation, mucocutaneous lesions, glycosuria, myalgia, hepatotoxicity, increased urinary frequency, 
hypotension, abnormal changes in ECG and gastrointestinal symptoms [21]. Prolonged treatment with 
CaNa2EDTA  results in depletion of essential metal, especially Zn, Cu and Mn [22].  It has been 
reported that zinc supplementation during and after chelation is also beneficial [23]. Although zinc 
depletion by CaNa2EDTA therapy is rapidly reversible by zinc supplementation, it is considered to be 
key mechanism for teratogenic effects of the drug, especially when administered between days 11 to 
14 at doses comparable to humans.  This allows the use of EDTA  as a research tool to study 
mechanisms and role of zinc dependent molecules at critical periods of pregnancy. CaNa2EDTA has 
the LD50 value of 16.4 mmol/kg in mouse [12]. The drug is contraindicated in pregnancy, active renal 
diseases or anuria, hepatitis, and hypersensitivity to edentate products [21].  
 
3.2. Calcium Trisodium DTPA 
 
Calcium or zinc trisodium diethylenetriaminepentaacetate (CaNa3DTPA or ZnNa3DTPA 
respectively) have been used against plutonium and other transuranic elements like californium, 
americium, and curium [24]. The drug is effective against cobalt and zinc poisoning in experimental 
models [25,26]. Its efficacy against acute cadmium poisoning is promising however is less effective as 
compare to carbodithioates [27,28].  
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Pharmacological Profile  
 
Like CaNa2EDTA, CaNa3DTPA/ZaNa3DTPA is poorly absorbed in the gastrointestinal tract, and 
thus they are parenterally administered and are distributed extracellularly. They may be administered 
by intravenous or intramuscular routes or by inhalation through a nebulizer [24,29], where the former 
are painful. CaNa3DTPA shows an expected disadvantage of depleting Zn from the system that may be 
overcome by supplementation or using the zinc salt of the drug. Despite this disadvantage, although 
CaNa3DTPA is still preferred over the Zn form due to its higher efficacy, it is not recommended for 
prolonged therapy. Although CaNa3DTPA is well tolerated, some adverse effects may be observed, 
including nausea, vomiting, diarrhea, chills, fever and muscle cramps during the first 24 hrs [29]. 
CaNa3DTPA is teratogenic like CaNa2EDTA due to its Zn and Mn depletion effect that is confirmed 
by the teratogenic effects of ZnNa3DTPA at a dose 16 times lower than CaNa3DTPA. Thus, although 
the drug is contraindicated during pregnancy ZnNa3DTPA may be carefully administered if 
unavoidable. Other contraindications include prescription to children, in patients with renal 
insufficiency and bone marrow depression.  
 
3.3. D-Penicillamine 
 
D-Penicillamine (DPA;  β-β-dimethylcysteine or 3-mercapto-D-valine) is  a sulfhydryl containing 
amino acid and a degradation product of penicillin. Only the D-isomer is used because the L-isomer 
causes optic neuritis. DPA is used mainly as a  chelating agent in heavy metal toxicity viz.  lead, 
mercury and copper poisoning (Wilson’s disease) [30].  
 
Pharmacological Profile 
 
DPA is well absorbed via the gastrointestinal tract and can be administered orally or by iv route. It 
is  approximately 50% absorbed orally and mainly follows extracellular distribution.  Peak plasma 
concentration is reached between 1 and 4 hours after oral administration. A minimal drug fraction 
under-goes hepatic metabolism to disulfides, and most of the drug is excreted unchanged in urine. 
Elimination half life ranges from 1 to more than 7 hours. Although low adverse reactions have been 
reported, some serious ones including thrombocytopenia and leukocytopenia (incidence 5–15%), and 
rarely aplastic anemia may occur. Prolonged  DPA  treatment may lead to anorexia, nausea  and 
vomiting. The ulcerogenic activity of DPA in rats, which may involve the stimulation of histaminergic 
(H1 and H2) receptors, has been reported [31]. Other toxic effects of DPA include gastrointestinal 
disturbances (10–30%), changes/loss of taste (5–30%), hair loss  (1–2%), and partly proteinuria   
(5–20%) [32]. Severe adverse effects are autoimmune phenomena such as pemphigus, DPA-induced 
lupus erythematosus, polymyositis/dermatomyositis, membranous glomerulopathy and 
hypersensitivity pneumonitis [32]. DPA is a well recognized teratogen and lathyrogen that causes 
skeletal, cutaneous and pulmonary abnormalities [31].  The most important contraindication is in 
patients allergic to penicillin and in cases of renal insufficiency. Co-administration of DPA to patients 
receiving gold therapy, antimalarial or cytotoxic drugs, phenyl-butazone, or oxyphenbutazone must be 
contraindicated since it can result in more serious adverse reactions. Int. J. Environ. Res. Public Health 2010, 7                 
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3.4. British Anti Lewisite (BAL)  
 
2,3-Dimercaprol (BAL) is a traditional chelating agent developed by British biochemists at Oxford 
University during World War II [33]. BAL has a 3-carbon backbone with two sulfhydryl (–SH) groups 
and a hydroxyl group. It has been used clinically since 1949 in arsenic, cadmium and mercury 
poisoning. It is an oily, clear, colorless liquid with a pungent, unpleasant typical mercaptan smell. It 
detoxifies lewisite by forming a five membered stable complex with arsenic (Figure 5). In humans and 
experimental models, the antidotal efficacy of BAL has been shown to be most effective when 
administered immediately after the exposure. Besides rapid mobilization of arsenic and mercury from 
the body, it causes a significant increase in brain deposition of arsenic and mercury compounds [34,35].  
Figure 5. Chemical reaction of lewisite with British Anti Lewisite (BAL) to give a stable 
5- membered ring complex. 
 
 
Pharmacological Profile 
 
Due to its oily nature, the drug is not absorbed orally and administration of BAL requires deep 
intra-muscular injection that is extremely painful and allergenic. It was found to mobilize and relocate 
lead to the brain, increasing its neurotoxic effects [36]. Although treatment with dimercaprol increases 
the excretion of cadmium, there is a concomitant increase in renal cadmium concentration, so its use 
should be avoided in cases of cadmium toxicity. The drug has a short half life. Thus, the major 
drawbacks of BAL include:  
1.  Low therapeutic index (small margin of safety)  
2.  Tendency to redistribute arsenic to brain and testes  
3.  Need for (painful) intramuscular injection  
4.  Unpleasant odor (rotten eggs)  
Other common adverse effects include fever, conjunctivitis (eye inflammation), lacrimation 
(tearing), constricted feeling (chest, limbs, jaw, abdomen), headache, paresthesias (tingling sensation), 
tremor, nausea, and pain at the injection site [37]. More serious complications may be infections 
(abscesses) at the injection site, liver damage, elevated blood pressure and heart rate, and hemolysis 
(destruction of red blood cells) in patients with glucose-6-phophate deficiency (G6PD) [37]. 
 
 
 
Lewisite  BAL 
5-membered ring complex of 
BAL and arsenic Int. J. Environ. Res. Public Health 2010, 7                 
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3.5. Meso-2,3-Dimercaptosuccinic Acid (DMSA) 
 
A  chemical derivative of dimercaprol which has gained more and more attention, is   
meso-2,3-dimercaptosuccinic acid (DMSA). DMSA is a dithiol compound (containing two sulfhydryl, 
or –SH, groups) and an analogue of dimercaprol (BAL). It was 40 years ago when initial studies 
identified DMSA as an effective antidote to heavy metal poisoning. Subsequently DMSA was studied 
for more than twenty years in the People’s Republic of China, Japan, and Russia before scientists in 
Europe and the United States “discovered” the substance and its potential usefulness in the   
mid-1970s [38].  
 
Pharmacological Profile 
 
The hydrophilic nature of DMSA  causes considerable absorption in  gastro intestinal tract thus 
possible oral route of administration creates its distinct advantage over BAL. The drug is 95 % plasma 
protein bound, most likely by virtue of binding on one of its sulfhydryl groups to a cysteine residue on 
albumin, leaving the other –SH available to chelate metals [39]. DMSA has a large therapeutic window 
and is the least toxic amongst the dithiol compounds [40]. No significant loss of essential metals like 
zinc, iron, calcium and magnesium are observed. However, metabolism of copper may be altered in 
humans after administration of DMSA [41].  A major drawback associated with DMSA is its 
extracellular distribution, since it is unable to cross the cell membrane. Adverse reaction of DMSA 
includes gastrointestinal discomfort, skin reaction, mild neutropenia and elevated liver enzymes. The 
LD50 value of sodium salt of DMSA is about 3% greater than that of DMPS [38], in mice it is: 2.4 for 
i.v., 3.8 for i.m., 4.4 for i.p., and 8.5 gm/kg for oral route.  
Figure 6. Limitations of DMSA in the treatment of mercury toxicity. 
 
- Mercury which mainly absorbs in lungs and finally gets distributed to soft tissues.  
- Altered copper metabolism following chelation with DMSA might also contribute towards 
redistribution of Hg from soft tissues to brain.  
 Int. J. Environ. Res. Public Health 2010, 7                 
 
2756 
Numerous animal and human studies have shown that DMSA administration increases urinary 
mercury excretion and reduces blood and tissue mercury concentration [42-44]. Chelation therapy with 
DMSA must be initiated shortly after exposure to prevent accumulation and avoid toxicity. Studies in 
animal models have shown that neither DMSA nor any other chelating or mobilizing agents were able 
to ameliorate the brain burden of mercury [45,46]. The treatment with DMSA after exposure to 
inorganic mercury caused an increased elevation of mercury into motor axons presumably owing to 
redistribution of mercury, which was mobilized from non-neural tissues (e.g., kidneys and liver) 
(Figure 6) [46]. 
 
3.6. Sodium 2,3 Dimercaptopropane-l-Sulphonate (DMPS)  
 
Sodium 2,3-dimercaptopropane sulfonate (DMPS) is another analogue of BAL. DMPS is not 
considered as an appropriate drug against lead toxicity. A pilot study of DMPS in lead poisoned 
children by Gersl and co workers indicates less efficiency than CaNa2EDTA and DMSA [47]. DMPS, 
although known for its antidotal efficacy against mercury, it has also been reported to have limited 
efficacy  for treating  lead and arsenic poisoning [18,48].  The drug is registered in Germany for 
treatment of mercury intoxication, but  it is not approved in the  United States, so unless special 
permission is given by the U.S. Food and Drug Administration, it is unlawful for physicians to use it in 
the United States, nor is it lawful for pharmacies to compound it. Still, DMPS is being illegally used 
by members of the alternative health industry to treat people allegedly suffering from mercury 
intoxication, most often claimed to be due to amalgam dental fillings. 
 
Pharmacological Profile 
 
DMPS, being hydrophilic in nature, is mainly distributed in the extracellular space but may enter 
cells by specific transport mechanisms.  Thus, DMPS is known to be  distributed both in the 
extracellular and to small extent in intracellular spaces [2]. DMPS appears to be bio-transformed in 
humans to acyclic and cyclic disulphides. The drug and its metabolites are rapidly eliminated from the 
body through the kidneys. It is important to note that this drug does not redistribute arsenic, lead, or 
inorganic mercury to the brain [49]. No major adverse effects following DMPS administration in 
humans or animals have been reported [49]. Adverse reactions during treatment with DMPS include 
gastrointestinal discomfort, skin reactions, mild neutropenia, and elevated liver enzymes. Some 
patients, especially those with allergic asthma symptoms, may develop hypersensitivity to DMPS [50]. 
Further, oral administration of DMPS did not adversely affects late gestation, parturition or lactation in 
mature mice and fetal and neonatal development do not appear to be adversely affected.  
 
3.7. New DMSA Analogues 
 
The known chelating agent DMSA has been found to have fewer side effects with greater efficacy. 
The heavy metal chelating property of DMSA is due to the presence of vicinal dithiol groups that may 
also act as an oxygen radical scavenger and thus inhibit lipid peroxidation, giving an added advantage 
of fighting heavy metal induced oxidative stress. However, its hydrophilic properties do not allow it to Int. J. Environ. Res. Public Health 2010, 7                 
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cross the cell membrane. It was recently observed that esters of DMSA might be more  effective 
antidotes for heavy metal toxicity. A large number of esters of DMSA have been synthesized aiming to 
for achieve optimal chelation and transport effects, compared to DMSA. These esters are mainly the 
mono- and diesters of DMSA that have been studied experimentally with the aim of enhancing tissue 
uptake of chelating agents. In order to make the compounds more lipophilic, the carbon chain length of 
the parent DMSA was increased by controlled esterification with the corresponding alcohol (methyl, 
ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl and hexyl) (Figure 7). It has also been 
reported that these mono and diesters have a better potential in mobilizing heavy metal from the tissues 
in mice [51]. Walker et al. [51] studied the effects of seven different monoalkyl esters of DMSA on the 
mobilization of lead in mice and observed that after a single parenteral dose of the chelator DMSA 
there was a 52% reduction in the lead concentrations while with the monoesters the reduction varied 
from 54% to 75%. In most of these published reports, it has been observed that the analogues of 
DMSA were capable of crossing the biomembranes and were more effective in reducing arsenic 
burden in acute and sub-chronic intoxication. These studies have also suggested that the monoesters 
may be preferred over DMSA diesters owing to their higher efficacy against arsenic intoxication and 
lower toxicity.  
Figure 7. Newly synthesized monoesters of DMSA. 
 
 
3.7.1. Monoisoamyl DMSA (MiADMSA) 
 
Monoisoamyl DMSA was synthesized by controlled esterification of DMSA with isoamyl alcohol. 
Controlled esterification made MiADMSA, a C5 branched chain alkyl monoester of DMSA which was 
lipophilic in nature as compared to the parent DMSA. Chelation studies with MiADMSA found it to 
be highly effective in reducing heavy metal burden  from various organs in heavy metal exposed   
animals [52,53].  
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Pharmacological Profile 
 
MiADMSA is a potential drug candidate that is still in its developmental phase thus, its entire 
pharmacological profile has not been established yet. However, studies to date highlight the efficacy 
and safety of the new molecule in lead and arsenic acute and chronic toxicity in experimental animals. 
Results suggest that MiADMSA administration increases the activity of ALAD, a specific lead toxicity 
biomarker in all the age groups and increased blood GSH levels in young rats. MiADMSA was also 
found to potentiate the synthesis of MT in liver and kidneys and GSH levels in liver and brain, along 
with significantly reducing  the GSSG levels in tissues. MiADMSA is capable of mobilizing 
intracellularly bound cadmium [54] and is seen to provide antioxidant functions by removing cadmium 
from the site of deleterious oxidation reactions. The reduced sulfhydryl groups in this compound may 
also participate in antioxidant reactions and possibly retard propagation of oxidative damage induced 
by cadmium. Recently Flora and Mehta [55] suggested reversal of arsenic-induced dysfunctioning with 
concomitant treatment of MiADMSA in vitro and in vivo. Employing IR spectroscopy they suggested 
that MiADMSA binds to arsenic to form an adduct which prevents arsenic from exerting its toxic 
effect in both models. Mehta and Flora, [56] reported for the first time the comparison of the role in 
metal redistribution of different chelating agents (three  amino and four  thiol chelators)  on 
hepatotoxicity and oxidative stress in chelating agent-induced metallothionein in rats. The interaction 
of MiADMSA and DMSA with essential metals is same. MiADMSA was found to be safe in adult rats 
followed by young and old rats [57]. Our group reported for the first time the toxicological data of 
MiADMSA, when administered in male and female rats through the oral as well as the intraperitoneal 
(i.p.) route (25, 50 and 100 mg/kg for three weeks). The oral route of administration was found better 
when compared to the i.p. route based on the histopathological studies of the liver and kidney tissues. 
MiADMSA was seen to be slightly more toxic in terms of copper loss and some biochemical variable 
in the hepatic tissue in females as compared to male rats [58,59]. The studies concluded that the 
administration of MiADMSA in female rats is confounded with side effects and may require caution 
during its use. No observed adverse effect levels (NOAELs) for maternal and developmental toxicity 
of MiADMSA were 47.5 mg/kg and 95 mg/kg/day, respectively, indicating that MiADMSA would not 
produce developmental toxicity in mice in the absence of maternal toxicity [60]. Mehta et al. [61] have 
suggested that MiADMSA had no effect on length of gestation, litter-size, sex ratio, viability and 
lactation. Taubeneck et al. [62] showed that the developmental toxicity of DMSA is mediated mainly 
through disturbed copper metabolism and this may also be true for MiADMSA. It is reported that the 
toxicity of DMSA with LD50 of 16 mmol/kg is much lower than the toxicity of MiADMSA with LD50 
of 3 mmol/kg, but lesser than BAL (1.1 mmol/kg). 
 
3.7.2. Monomethyl DMSA (MmDMSA) and Monocyclohexyl DMSA (MchDMSA)  
 
MmDMSA has a straight and branched chain methyl group, while MchDMSA has a cyclic carbon 
chain. Thus, they both have better lipophilic characteristics and might penetrate cells more readily that 
extracellularly acting chelating agent like DMSA. Both these chelating agents are orally  active.  
Jones et al. [54] in their in vivo study on male albino mice exposed to cadmium for seven days, 
observed that administration of MmDMSA and MchDMSA produced significant reductions in whole Int. J. Environ. Res. Public Health 2010, 7                 
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body cadmium levels. Further, no redistribution of cadmium  in brain was observed. The in vivo 
evaluation of these monoesters derived from higher alcohols (C3–C6 monoesters) proved to have better 
efficacy as compared to the monoesters derived from lower ones (C1–C2  monoesters) [54]. Their 
ability to be administered orally suggests that they may possess considerable advantages in the clinical 
treatment of lead toxicity however; extensive studies are further required to reach a final conclusion. 
 
3.8. Deferoxamine (DFO) 
 
Deferoxamine is a trihydroxamic acid, siderphore secreted by Streptomyces pilosus, a fungus. This 
chelating agent is known for its strong binding affinity for trivalent iron and less affinity for other 
metals making it a specific chelating agent for iron related diseases such as thalassaemia major as well 
as aluminium poisoning associated with chronic renal dialysis.  
 
Pharmacological Profile 
 
The absorption of DFO in the gastrointestinal tract is low and thus it is administered mainly through 
intravenous injection or infusion. It is mainly distributed extracellularly and the protein binding in 
plasma is low (<10%). It complexes with iron and is excreted rapidly as ferrioxamine, mainly through 
kidney and one third into bile through faces. Thus, its efficacy also is determined by adequate urine 
output and may be facilitated by dialysis in case of dysfunctioning. This drug is generally well 
tolerated with few cases where side effects include opthalamic and auditory toxicity, bacterial and 
fungal infections, alterations in blood histology, allergic and skin reaction besides few reported adverse 
effect on lungs, kidney and nervous system [63]. The total intravenous dose of deferoxamine should 
generally not exceed 80 mg/kg/24 hours. The intramuscular route of administration is not 
recommended in circulatory shock states.  
 
3.9. Deferiprone (L1) 
 
Deferiprone (L1; CP20; 1,2-dimethyl-3-hydroxypyrid-4-one) is an iron chelator and is considered a 
suitable alternative to deferoxamine in the trasfusional iron overload [64]. It is comparatively less 
expensive than deferoxamine. Clinical studies suggest that combined administration of deferoxamine 
and deferiprone for three days per week is very effective in depleting iron overload accompanied by 
improvement in the cardiac function in transfusion dependent thalassemia patients. It may be noted 
that deferoxamine is known for reversal of cardiac dysfunction, and  deferiprone has also shown   
cardio-protective effects. These may be attributed to reduction in iron overload however, the specific 
mechanism is not clear. Besides, due to higher incidences of agranulocyrosis, treatment must be 
closely monitored [65].  
 
Pharmacological Profile 
 
 The major advantages include oral administration and rapid absorption through gastrointestinal 
tract.  L1 is mainly excreted via renal route and has a half life of 47–134 minutes.  Dosages of   Int. J. Environ. Res. Public Health 2010, 7                 
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75–100 mg/kg body weight/day of L1 have been considered effective to maintain stable iron balance 
and to reduce serum ferritin levels within one year of treatment in iron-overloaded thalassemic patients. 
L1 is rapidly absorbed mainly from the stomach and reaches the circulation quickly. However, they 
might be the possibility of food–drug interaction or other gastric factors that delays the appearance of 
the drug in blood following oral administration. L1 is mainly metabolized as glucoronide conjugates 
and excreted from urine. Wide variation in the metabolism and clearance of L1 amongst patients have 
been observed, which mainly depend on iron overload and availability of chelatable iron [66]. The 
main reported side effects during a deferiprone therapy are arthropathy, gastrointestinal symptoms, 
headache, and moderate zinc deficiency. These adverse reactions are usually reversed on reducing the 
dose or discontinuing the drug. Except for severe joint symptoms in few patients, most of the subjects 
in different clinical trials have been able to continue with L1 therapy for a long term. The most severe, 
but rare complication following administration of deferiprone is agranulocytosis or neutropenia.  
 
3.10. TETA  
 
Tetraethylenetetraamine or trientine is a drug of choice for acute copper intoxication. Although 
nowadays there is less use of copper utensils, in ancient times the use of copper utensils could lead to 
extensive exposure to copper. Increased urinary copper excretion has been reported after 
administration of TETA [2].  
 
Pharmacological Profile 
 
Normally TETA is administered through the oral route but its absorption is relatively poor, as 
indicated by the as evident from the recovery observed in urine and caracass after administration of an 
oral dose of C
14-labeled TETA.  Two major metabolites of TETA have been identified,  i.e.,  
N1-acetyltriethylenetetramine (MAT) and N1,N10-diacetyltriethylenetetramine (DAT). The former plays a 
significant role in the molecular mechanism by which TETA extracts copper from the system. The 5–18% 
of TETA that is systemically absorbed is said to be extensively metabolized, with the majority being 
excreted in urine as metabolite(s) [67,68]. Wilson’s disease is characterized by disturbance in copper 
homeostasis which is inherited and leads to progressive increase in accumulation of copper and may 
even be fatal if not cured. Wilson’s disease was originally treated with DPA but TETA was a better 
chelator and found to be potentially free of side effects like those of DPA. The recommended dosage 
to treat Wilson’s disease patients is 0.75–2 g/day. The oral LD50 for rats for TETA is 2.5 g/kg body 
weight and is very close to the recommended dose for treatment of Wilson’s disease.  
 
3.11. Nitrilotriacetic Acid (NTA) 
 
Nitrilotriacetic acid (NTA, C6H9NO6), is a polyamino carboxylic acid and is also used as a chelating 
agent which forms coordination compounds (chelates) with metal ions such as Ca
2+, Cu
2+ or Fe
3+. The 
uses of NTA are quite similar to EDTA. However, in contrast to EDTA, NTA is easily biodegradable. 
NTA is available in two forms, one that is a sodium derivative (Na3NTA) and the other iron (FeNTA). 
Both of these forms have been used as chelating agents [69]. Int. J. Environ. Res. Public Health 2010, 7                 
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NTA has been used shown to possess the ability to mobilize nickel from brain, heart, kidney and 
liver of nickel poisoned rats. In a comparative study with six metal binding agents, NTA was highly 
effective in dialyzing out nickel from the subcellular fractions of liver, kidney and blood corpuscles in 
rats that were exposed to nickel sulphate [70]. Apart from nickel mobilization, a single dose of NTA 
has been tried in the removal of manganese from various organs and plasma in rats. Results from these 
studies have indicated that NTA binds rapidly to Mn and forms stable and diffusible complexes that 
result in faster excretion of Mn from the rats [71]. Since NTA is considered to be non-mutagenic  
in vitro [72] an epigenetic mechanism is assumed, based on the fact that there is sustained cytotoxicity 
of zinc ions transfer to the urinary tract [72]. Vacuolated cells of the proximal tubules represent the 
earliest lesions [73], followed by sloughing, necrosis/apoptosis, and proliferation [74-76]. With chronic 
application of a high dose level, these alterations lead as a continuum to hyperplastic foci, adenomas, 
and adenocarcinomas [77]. This ability of both NTA to form tumors cannot be ruled out. Studies 
however have indicated that tumor formation ability of both NTA is highly route and dose 
dependented. While FeNTA causes an iron overload and lipid peroxidation in cells and is   
genotoxic [78,79], Na3NTA predominantly binds to zinc and calcium, thereby exerting its toxic   
effects [72].  
 
4. Limitations of Current Chelation Therapy 
 
Most of the currently used chelating agents have serious side effects [80]. Since possible adverse 
effects and risk associated with conventionally used chelators has already been highlighted in the 
previous sections, mechanistic limitations are addressed here. CaNa2EDTA is a general chelating agent 
that complexes a wide variety of metal ions and is used clinically despite associated risks. 
CaNa2EDTA cannot pass through cellular membranes and therefore its use is restricted in removing 
metal ions from their complexes in the extracellular fluid. Similarly conventionally used succimer, 
DMSA although is considered safer, it shares the limitation of extracellular distribution. The latter 
renders the drug effective in cases of slow, low dose, chronic metal poisoning (especially lead and 
arsenic) since metal reaches the cellular compartments behind the physiological barriers including the 
blood brain barrier. One such classical example was demonstrated during the clinical trial conducted in 
Bangladesh where DMSA was found ineffective in patients chronically exposed to arsenic [81]. Thus, 
it  is of immediate environmental health concern to identify the limitations of currently available 
chelating agents and develop new drugs that are more effective in the cases of low, long term exposure 
to toxic metal. Although treatment with DMSA and DMPS has shown lesser adverse effects, essential 
metal loss in particular of copper and zinc may be considered as one of the serious notable limitations. 
Specificity for the target metal may be another domain that needs to be addressed during new drug 
development.  D-Penicillamine  (DPA)  exhibits disadvantage of possible risk to cause anaphylactic 
reaction in patient allergic to penicillin. Also prolonged use of DPA may induce several cutaneous 
lesions, dermatomyosites, adverse effects on collagen, dryness,  etc.  We have summarized the 
beneficial and the drawbacks associated with chelation therapy are presented in Figure 8.  
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Figure 8. Benefits and drawbacks of chelation therapy. 
 
A retrospective examination of various antidotes reveals that there is no global unanimity of opinion 
regarding the efficacy of a particular treatment regimen. This is mainly due to different experimental 
conditions, test protocols and species of animals employed in evaluating various antidotes. Adoption of 
a particular treatment in a country is dictated by various factors including the regulatory bodies and the 
legislations. Also, the toxicity of a particular treatment regimen is overlooked in a particular country 
where as in other countries it is the reason for rejection. The success of any treatment relies on the fact 
that: (i) it is fast-acting, (ii) has long half and shelf lives, (iii) has minimal side effects and (iv) has ease 
of application. 
The reason to look for newer antidotes are that: (i) there is no effective and safe pre-treatment 
available which could be instituted as preventive measure against possible arsenic exposure, (ii) the 
recommended treatments have serious limitations like side-effects or are contraindicated for various 
instances of heavy metal poisoning, (iii) most of the available treatments are to be given intravenously 
by a medical practitioner and under no circumstances victim can resort to self aid, (iv) there is no safe 
and effective oral treatment available and (v) there is no fast acting antidote available which could 
immediately remove toxic metal from blood and soft tissues. It is thus clear from above that most of 
the conventional chelators are compromised with many side effects and drawbacks and there is no safe 
and effective treatment available for heavy metal poisoning.  
5. Newer Strategies: Combination Therapy 
A new trend in chelation therapy is to use two structurally different chelators (Table 2). The concept 
of combination therapy lies on the fact that two prescribed drug will act through different mechanism 
of action, thus resulting in additional effect, or sometimes they may support each others’ mode of 
action leading to synergism. The idea of using combined treatment is based on the assumption that 
various chelating agents are likely to mobilise toxic metals from different tissue compartments and 
therefore better results could be expected [18,82]. The combination therapy is an approach to ensure 
enhanced metal mobilization from the body, reduction in the dose of potential toxic chelators, and no 
redistribution of toxic metal from one organ to another following chronic metal exposure [18,83-85]. 
The principle mechanism behind administration of two structurally different chelating agents is 
Chelation 
 
 
Effective against acute poisoning 
Form non-toxic complexes 
Remove metal from soft tissues 
Oral therapy is available 
 
Benefits   
 
Redistribution of toxic metal 
Essential metal loss 
No removal of metal from intracellular sites 
Hepatotoxicity and nephrotoxicity 
Poor clinical recovery 
Pro-oxidant effects (DTPA) 
Headache, nausea, increased blood pressure 
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illustrated in Figure 9. Flora et al.  [18] observed that combined administration of DMSA and 
CaNa2EDTA against chronic lead poisoning lead to a more pronounced elimination of lead and better 
recoveries in altered lead sensitive biochemical variables besides no redistribution of lead to any other 
organ, was noticed. Co-administration of DMSA and MiADMSA at lower dose (0.15 mmol/kg) was 
most effective not only in reducing arsenic-induced oxidative stress but also in depleting arsenic from 
blood and soft tissues compared to other treatments [86].  
Treating experimental animals with MiADMSA along with DMSA, we could not only ensure 
enhanced arsenic elimination but also minimize many serious side-effects, leading to better therapeutic 
efficacy of the chelators [87]. Since MiADMSA is lipophilic it can chelate intracellular toxic metal and 
make it accessible to extracellularly available DMSA which may then facilitate rapid excretion of 
metal from the body. DMSA and MiADMSA in addition to acting as a metal chelator could also act as 
an antioxidant [88]. The sulfhydryl groups present in these chelators may interact with free oxygen 
radical or by product of lipid peroxidation like lipid hydroperoxides and aldehydes produced by heavy 
metal thereby reducing oxidative stress.  
Figure 9. Beneficial effects of combination therapy. 
 
Moreover, the combined administration of DMSA and MiADMSA in chronically arsenic exposed 
animals was also able to protect against hepatic DNA damage. This observation greatly strengthens the 
possibility that co-administration of two chelating agents not only gives better efficacy in terms of 
recovery from arsenic-induced oxidative stress but also helps in reducing the dose of a potentially toxic 
chelator, thereby minimizing the possible side effects [87]. A reduced dose of chelating agent was 
found to be beneficial against lead toxicity, with optimum efficacy in the altered biochemical variables 
and body burden of lead [87]. Recently it has been reported that combined administration of thiol 
chelator (MiADMSA) and CaNa2EDTA is beneficial against chronic lead toxicity in terms of altering 
neurotransmitters level, neurobehavioral changes, and markers of apoptosis [83]. It was also beneficial 
in reducing body lead burden and neuronal cell death [83]. Combined administration of DMSA and 
MiADMSA has found to be highly effective in not only reducing lead burden but also provide better 
clinical recoveries especially in the brain than monotherapy [89]. Thus, combined administration of 
DMSA and MiADMSA is recommended for achieving optimum effects of chelation therapy. Figure 
10  describes effects of acute and chronic metal exposure and various preventive and therapeutic 
measures against it.  
Lipophilic + Lipophobic 
 (Intracellular Metal)     (Extracellular Metal) 
Combination Therapy 
(Incorporation of Two Structurally different chelating agents) 
Enhanced metal decorporation 
Reduction in magnitude of the dose 
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 Figure 10. Acute and chronic exposure symptoms of  metal toxicity and possible 
preventive and therapeutic measures against them. 
 
 
6. Oxidative Stress in Metal Toxicity and the Role of Antioxidants 
 
Arsenic is one of the most extensively studied metals that induce ROS generation and results in 
oxidative stress. Experimental results show that superoxide radical ion and H2O2 are produced after 
exposure to arsenite in various cellular systems [48,86,90]. Shi et al. [91] provided evidence that 
arsenic generates free radicals that leads to cellular damage and death through the activation of 
oxidative sensitive signaling pathways. ROS play a significant role in altering the signal transduction 
pathway and transcription factor regulation. Numerous reports have indicated that arsenic affects 
transcriptional factors either by activation or inactivation of various signal transduction   
cascades  [92,93]  Arsenic is known not only to produce ROS but also, nitric oxide (NO•) 
dimethylarsinic peroxyl radicals (CH3)2AsOO• and also the dimethylarsinic radical (CH3)2As• [94,95]. Int. J. Environ. Res. Public Health 2010, 7                 
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Oxidative DNA lesions induced by arsenic were observed both in vivo  [96] and in vitro  [97,98] 
studies. In a study by Schiller et al. [99] it was shown that arsenite can inhibit pyruvate dehydrogenase 
(PDH) activity through binding to vicinal dithiols in both the pure enzyme and tissue extract. The 
mechanism of arsenite toxicity was reported owing to its effects on the generation of the hydroxyl 
radical [100].  
Cadmium, unlike other heavy metals is unable to generate free radicals by itself, however, reports 
have indicated superoxide radical, hydroxyl radical and nitric oxide radicals could be generated 
indirectly [101]. Watanabe et al. [102] showed generation of non-radical hydrogen peroxide which by 
itself became a significant source of free radicals via the Fenton chemistry. Cadmium could replace 
iron and copper from a number of cytoplasmic and membrane proteins like ferritin, which in turn 
would release and increase the concentration of unbound iron or copper ions. These free ions 
participate in causing  oxidative stress via the Fenton reactions [103-105]. Acute intoxication of 
animals with cadmium has shown increased activity of antioxidant defense enzymes like copper-zinc 
containing superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and 
glutathione-S-transferase [106].  
Although various mechanisms have been suggested for the toxic effects of Hg,  no single 
mechanism explains all of the pathological outcomes. The chemical reactivity of the metal suggests 
that oxidative stress might be involved in Hg-induced toxicity. GSH, the primary intracellular 
antioxidant, was shown to be depleted and to have impaired function in Hg toxicity [107]. 
Oxidative stress may be considered as one of the prime contributing mechanism in metal toxicity 
and thus provide  a  strong rationale for including antioxidants during chelation therapy  (Table 2). 
Antioxidant supplementation with chelating agents has been found beneficial in increasing lead 
mobilization and providing recovery of altered biochemical variables [108,109]. Combinational 
therapies with antioxidants like N-acetylcysteine (NAC) [53], lipoic acid (LA) [109], melatonin [53], 
and gossypin [110] have shown considerable promise in improving clinical recoveries in animal 
models. MiADMSA alone or in combination with captopril was significantly effective in reversing  
lead-induced apoptosis [111]. We noted significant effect of taurine in depleting blood, liver, kidney 
and brain lead and arsenic levels, respectively, when co-administered with DMSA  or  
MiADMSA [112,113]. This suggests that the antioxidant capacity of taurine becomes most effective 
when it is administered along with the thiol chelators or taurine might be facilitating the entry of 
chelator to the intracellular sites thereby reducing arsenic concentration. NAC is known to have metal-
chelating properties and has been used in several clinical conditions [114]. Thiol groups present in 
NAC act to reduce free radical and provide chelating site for metals. Combined administration of NAC 
and succimer post arsenic exposure led to a significant turnover in the variables indicative of oxidative 
stress and removal of toxic metal (arsenic) from the soft organs [115]. Pande et al. [116]
 suggested that 
NAC could be used both as preventive as well as therapeutic agent along with MiADMSA/DMSA in 
the prevention or treatment of lead intoxication in rats. Co-administration of vitamin C and 
MiADMSA in reducing liver and kidney arsenic burden supports the view that vitamin C acts as 
detoxifying agent by forming a poorly ionized but soluble complex [108]. Recently we have also 
reported that interaction of non-metal (fluoride) with metalloid (arsenic) also lead to some antagonistic 
effects [117]. Lipoic acid might also have the capability to interfere with the absorption of arsenic. 
Beneficial role of LA against lead [109] and GaAs [118] toxicity in terms of lead and arsenic chelation Int. J. Environ. Res. Public Health 2010, 7                 
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form blood and soft tissues have also been reported. Recently, the clinical importance of herbal drugs 
has received considerable attention (Table 2). Combination treatment with the thiol chelator and the 
natural antioxidant Centella asiatica proved to be beneficial in the recovery from lead-induced 
oxidative stress, including the level of biogenic amines and body lead burden as compared with the 
monotherapy [119].  
Table 2. Therapeutic strategies to address limitations in conventional chelation therapy.  
Therapeutic 
Strategy 
Examples  Refs.  Benefits 
Development of 
newer chelating 
agents 
MiADMSA 
MmDMSA 
MchDMSA 
[86] 
- Better therapeutic efficacy. 
- Access to intracellularly bound 
metals. 
- Lesser adverse drug reactions. 
- Better specificity. 
Combination 
therapy with two 
chelating agents 
DMSA+ MiADMSA  
MiADMSA+CaNa2EDTA  
[52,87,89] 
[85] 
- Better chelation efficacy  
- Removal of intra- and extra-cellular 
metals. 
- Prevents metal redistribution  
- Reduction in dose. 
- Lesser adverse effects  
Chelating agent 
+ Antioxidants 
DMSA/MiADMSA + NAC  
DMSA/ MiADMSA + LA 
MiADMSA+ Quercetin 
DMSA/ MiADMSA + Taurine 
DMSA/ MiADMSA+ Vitamin 
[115,207] 
[109] 
[132] 
[112,113] 
[205,108,120] 
- Metal chelation and protection 
against ROS. 
- Reestablish Pro/Antioxidant status. 
- Protects from oxidative stress.  
Chelating agent 
+ Micronutrients 
DMSA+Zn  
CaNa2EDTA+Zn 
Fe 
DMSA+Cu  
[16,122,121] 
[111] 
[208] 
[121] 
 
- Modifies toxicokinetics of metals. 
- Replenish essential metal loss  
- Cofactors for crucial antioxidant 
and metabolizing enzymes. 
Chelating agent 
+ Herbal extract. 
Centella asiatica Moringa 
Oleifera 
Garlic 
[209] 
[210] 
[211] 
 
- Plant extracts have been shown to 
potentiate the efficacy of chelating 
agents. 
- Herbal drugs are safer according to 
traditional claims. 
- Herbal extracts provide the benefits 
of natural chelation properties and 
antioxidant benefits.  
 
Administration of C. asiatica during chelation provided more pronounced effects, particularly in the 
recovery of oxidative stress parameters, suggesting that with the removal of lead from the target tissue, 
this antioxidant provides effective reversal in the altered parameters indicative of oxidative stress. 
Number of studies have been reported where a co-administration of a dietary nutrients like a vitamin 
e.g., thiamine [120], an essential metal viz. zinc [121,122] or an amino acid like methionine [123] with 
a chelating agent lead to many beneficial effects like providing better clinical recoveries as well as Int. J. Environ. Res. Public Health 2010, 7                 
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mobilization of heavy metal. Supplementation of trace metals has been found to be more effective 
when given during the course of chelation therapy compared to the chelating agents alone [23,124]. 
Iron, in vitro, is a good chelator of arsenic [125]. Simultaneous supplementation of zinc was found to 
effectively reverse  inhibition of the  lead sensitive zinc dependent enzyme ALAD in male Wistar   
rats [126,127]. When zinc was administered prior to arsenic, there was a reduction in arsenic 
concentration in several parts of the organism of adult mice, contributing to a decrease in toxicity from 
the metal [128]. It was also well established that the biosynthesis of metallothionein can be influenced 
by zinc. The role of zinc supplementation during the course of chelation of lead [23] and   
cadmium [129,130] has been reported to have many beneficial effects. A more effective removal of 
hepatic arsenic and recoveries in the arsenic sensitive biochemical indices following combined 
administration of zinc and MiADMSA [124] may offer an answer to the problem raised with 
MiADMSA monotherapy [56,57]. Various trends in combination therapy and their beneficial aspects 
have been summarized in Figure 11.  
Figure 11. showing possible mechanism involved for the better therapeutic efficacy of 
combined chelation therapy in lead/ arsenic poisoning using two different chelating agents. 
 
 
Phenolic compounds acting as antioxidants may function as terminators of free radical chains and as 
chelators of redox-active metal ions that are capable of catalyzing lipid peroxidation [131]. Mishra and 
Flora [132] have also reported that the combined treatment with quercetin and MiADMSA was not 
only able to chelate arsenic from the cell but also ameliorate oxidant levels, i.e., abatement of toxic 
effects of arsenic. Combined treatments with MiADMSA + NAC and MiADMSA + mannitol were 
effective both in terms of recovery in parameters of oxidative stress and reduction in blood and tissue 
cadmium burden [133]. These combined treatments were also effective in partially correcting the 
cadmium induced loss of liver and brain endogenous zinc. It has been reported that co-treatment with 
NAC reduces lipid peroxidation and prevents Cd-induced hepatotoxicity [134]. NAC besides 
preventing hepatotoxicity and reducing the rate of CdMT release from the liver, protect directly by 
forming a complex with Cd [135], or indirectly by scavenging free radicals [136] or by serving as a 
cysteine donor for GSH synthesis. 
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7. Therapeutic Recommendations for Heavy Metal Poisoning 
 
Metal poisoning may be acute, sub acute or chronic. Usually acute poisoning is well defined and 
identifiable, with serious rapid manifestations that may be recovered with immediate medical attention. 
However, the sub chronic that may convert to chronic metal toxicities may be ill defined as general ill 
health and not identifiable as any classical syndrome. Moreover, the chronic toxicities may be 
reversible or irreversible leading to slow development of manifestations like cancer or teratogenic 
malformations after latent period. The treatment of acute metal poisoning involves emergency medical 
care that may not be described in the present review. The present review will follow outline of general 
and specific metal toxicity management. Basic principles of metal toxicity management deals with step 
by step protocol, for easy understanding that follows as under: 
(1) Prevention of further metal absorption into the system 
(2) Elimination of metal from the circulation 
(3) Inactivation of metal bioavailable in the system 
Steps 1 and 2 are more applicable in cases of acute metal poisoning and step 3 is more directed to 
sub chronic or chronic metal toxicities [137]. 
 
7.1. Prevention of Further Metal Absorption into the System 
 
The most important and immediate measure is to remove the patient from the exposure. Toxic 
metals  may be absorbed by various routes of exposure including inhalation, dermally  or orally. 
Depending on the intensity and extent of exposure further treatment is decided. In case of high metal 
exposure as vapours of Hg or concentrated fumes of Pb or As gas, immediate removal of patient not 
only from the site but removal of clothing, decontamination of skin, eyes, hair and the area around 
followed by emergency medical assistance may be needed, whereas in case of chronic occupational 
exposures, or exposure due to lifestyle (household, contaminated drinking water, food, utensils, etc.) 
removal from exposure that may or may not be followed by immediate therapy is needed. The normal 
excretory system may expel metals to provide a gradual recovery from mild toxicity. In cases of 
ingestion of toxic metals, acute cases will need stomach emptying within four hours of metal ingestion, 
or inactivation of metal in the stomach beyond four hours or when gastric emptying is not possible. 
Various inactivating antidotes,  including activated charcoal, milk, egg white, sodium bicarbonate, 
sodium or magnesium sulphate, Prussian  Blue,  etc.  may be used for specific metals that are not 
discussed herein. 
 
7.2. Elimination of Metal from the Circulation 
 
After metal absorption into the circulation in acute cases it may be eliminated from the body to 
avoid further distribution and penetration in tissues;  thus reduce serious damage. Techniques like 
inducing diureses, modulating urinary pH for metal excretion, employing complexing agents to 
enhancing faecal excretion for metals undergoing extensive enterohepatic circulation or haemodialysis 
may be employed.  Int. J. Environ. Res. Public Health 2010, 7                 
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Although these techniques sounds promising there applicability and efficacy varies depending upon 
physicochemical properties of metal, route of exposure, intensity and extent of exposure and condition 
of the patient.  
 
7.3. Inactivation of Metal Bioavailability in the System 
 
7.3.1. Lead  
 
The clinical manifestation of lead toxicity is termed ‘plumbism’ and has been known since ancient 
times. Children are more vulnerable to lead exposure than adults because of the frequency of hand-to-
mouth activity (pica), and a higher rate of intestinal absorption and retention. Blood lead has been 
reported to impair normal metabolic pathways in children at very low levels [138]. Centers for Disease 
Control and Prevention determined that primary prevention activities in children should begin at blood 
lead levels (BLLs) > 10 μg/dL [139]. Lead (Pb) binds to sulfhydryl and amide group components of 
enzymes, altering their configuration and diminishing their activities. It  may also compete with 
essential metallic cations for binding sites, inhibiting enzyme activity, or altering the transport of 
essential cations such as calcium  [83].  Lead produces a range of effects, primarily on the 
haematopoietic system, the nervous system, and the kidneys. Lead inhibits many stages in the haem 
synthesis  pathway.  δ-aminolevulinic acid dehydratase (ALAD), which, catalyses the formation of 
porphobilinogn from δ-aminolevulinic acid (ALA) and ferrochelatase, which incorporates iron into 
protoporphyrin  [140]. ALA in urine has been used for many years as an  indicator of exposure, 
inhibition of haematopoiesis among industrial workers, and the diagnosis of lead poisoning [140,141]. 
Ferrochelatase catalyzes the incorporation of iron into the porpohyrin ring. As a result of lead toxicity, 
the enzyme is inhibited and zinc is substituted for iron, and zinc protoporphyrin concentration is 
increased  [142].  The most vulnerable target of lead poisoning is the nervous system.  Lead 
encephalopathy rarely occurs at blood lead below 100 µg/dL. One of the important mechanisms known 
for lead induced neurotoxicity is the disruption of calcium metabolism. Oxidative stress, a condition 
describing the production of oxygen radicals beyond a threshold for proper antioxidant neutralization, 
has been implicated as a pathologic condition in lead toxicity. Studies have shown that lead causes 
oxidative stress by inducing the generation of reactive oxygen species (ROS) and weakening the 
antioxidant defence system of cells [143,144]. Depletion of cells’ major sulfhydryl reserves seems to 
be an important indirect mechanism for  oxidative stress that is induced by redox-inactive  
metals [145,146].  
Other than the supportive therapy for lead exposed subjects, chelation therapy is recommended in 
symptomatic cases or where blood lead levels are high (50–60 µg/dL) [12]. The recommended dose of 
CaNa2EDTA for asymptomatic  adult  and pediatric  patients with blood lead concentration below   
70 µg/dL but above 20 µg/dL is 1,000 mg/m
2/day given intravenously (iv) or by intramuscular (im) 
route. The iv administration of CaNa2EDTA must always be as infusion over a period of 8–12 hrs, 
where by im route the drug is administered as two doses given at 8–12 hr intervals. However, in 
patients with blood lead levels higher than 70 µg/dL monotherapy with CaNa2EDTA might actually 
aggravate symptoms. These cases must receive combination treatment of CaNa2EDTA with BAL. 
Similarly, for lead encephalopathy in infants, immediate CaNa2EDTA iv infusion (1,500 mg/m
2/day) is Int. J. Environ. Res. Public Health 2010, 7                 
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administered for five days and complimentary BAL (450 mg/m
2/day) is recommended four hours 
before and during CaNa2EDTA treatment to avoid lead brain redistribution. Initial therapy increases 
urinary lead excretion and reduced blood lead burden which is usually followed by a rebound high 
blood lead concentration at chelation cessation. This happens by virtue of redistribution (mobilization) 
of metal from reservoirs like skeletal system. Thus, after a two day interval a second course of therapy 
is prescribed to allow redistribution of lead and replenishment of zinc and other essential metals. 
Further, anticonvulsive drugs (e.g., Phenytoin) or hyperosmotic (e.g., Dexamethasone) therapy may be 
added to CaNa2EDTA infusion if needed. CaNa2EDTA although is effective but is contraindicated in 
patients with renal insufficiency. Since the lead-EDTA complex is excreted by glomerulus filtration it 
aggravates chances of renal failure. In adults with lead nephropathy, CaNa2EDTA may be prescribed 
at the dose of 500 mg/m
2 at various time intervals for five days that may be repeated after a month 
interval depending upon serum creatinine levels. Dimercaprol was initially prescribed as monotherapy 
at a dose of 4 mg/kg, im at various intervals up to seven days. This is no longer in use due to its 
adverse effects and availability of safer chelators like DMSA.  In less severe  cases DMSA   
(30  mg/kg/day) can be conveniently prescribed for its oral administration and fewer side effects. 
DMSA has been approved by the U.S. Food and Drug Administration (US FDA) for the treatment of 
lead intoxication in children with blood lead levels 45 μg/dL. A major advantage of DMSA is that, 
lead is not redistributed to the brain and other vital organs after its therapy in rats intoxicated with  
lead [18,84]. Animal studies suggest that DMSA is an effective chelator of lead concentrated in soft 
tissue but it is unable to chelate lead from bones [142]. Ercal et al. [148] indicated that lead induced 
oxidative stress responded moderately to the treatment with DMSA accompanied by reduction in lead 
concentration from blood and soft tissue. DMSA for being an antioxidant and a strong lead chelator 
has been shown to deplete significantly lead from hippocampus leading to recovery in the oxidative 
stress and apoptosis induced by lead [149]. DMSA binds with lead utilizing –SH groups. Although D-
penicillamine also shared advantage of oral administration when prescribed at 250 mg given four times 
for five days of therapy or 40 mg/kg/day for chronic therapy; it is no longer used for the treatment of 
lead intoxications as safer profile succimer is available [12]. It is important to note that in cases of 
occupational lead poisoning, chelation therapy with ongoing exposure is never recommended. Instead 
patient heavily exposed to lead may be removed from the site and then only then chelation therapy 
should be administered.  
 
7.3.2. Arsenic 
 
Arsenic is listed as the highest priority contaminant on the ATSDR/EPA priority list of hazardous 
substances at Superfund sites  [150]. Major anthropogenic sources of arsenic in the environment 
include smelting operations and chromated copper arsenate, a variety of pesticide used in pressure 
treating wood for construction purposes. Arsenic can be transmitted not just by drinking water, but also 
by direct exposure to skin and hair. It can also be transmitted through food grains and the possible 
transmit of arsenic through summer (Boro) rice grown in the Bengal basin is an issue of debate [151]. 
High levels of arsenic have been found in 10 developing countries, including India [152,153]. In 
Bangladesh, 57.5% of the studied population had skin lesions caused by arsenic poisoning (n = 1,630 
adults) [154]. Arsenic toxicity is associated with various hepatic, renal, neurological and skin disorders. Int. J. Environ. Res. Public Health 2010, 7                 
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At chronic exposure it is known to also  produce carcinogenic effects. Arsenic  is rapidly and 
extensively accumulated in the liver, where it inhibits NAD-linked oxidation of pyruvate or   
α-ketoglutarate. This occurs by complexation of trivalent arsenic with vicinal thiols necessary for the 
oxidation of this substrate [115]. Dermatological changes following chronic arsenic intoxication are 
common features and the initial clinical diagnosis is often based on hyper pigmentation, palmar and 
solar keratosis. Toxic effects of arsenic also include changes in behavior, confusion, and memory loss. 
Exposure to arsenic in drinking water has been associated with a decline in intellectual function in 
children. Arsenic is classified as a group 1 carcinogen to humans based on strong epidemiological 
evidence [155]. Areas in Bangladesh and India with arsenicosis showed high incidences of tumors in 
local residents [156]. The mechanisms by which arsenic causes human cancers are not well understood. 
Recent in vivo studies indicate that methylated forms of arsenic may serve as co-carcinogens or tumour 
promoters [157,158]. One of the important mechanisms of arsenic induced disorders is its ability to 
bind with sulfhydryl group (–SH) containing molecules.  
Dimercaprol, at a dose of 3–4 mg/kg im every 4 to 12 hrs could be followed by penicillamine for  
four days, as four divided doses may be given to a maximum of 2 gm/day. Succimer or DMSA has 
been tried successfully in animal as well as in cases of human arsenic poisoning [159]. DMSA is also 
efficacious against arsenic toxicity however USFDA has approved DMSA only for lead chelation in 
children. We also reported significant depletion of arsenic and a significant recovery in the altered 
biochemical variables of chronically arsenic exposed rats [140]. However in a double blind, 
randomized controlled trial study conducted on few selected patients from arsenic affected West 
Bengal (India) regions with oral administration of DMSA suggested that DMSA was not effective in 
producing any clinical and biochemical benefits or any histopathological improvements of skin   
lesions [160]. 
 
7.3.4. Cadmium 
 
Cadmium (Cd) is one of the most toxic metal ions of our environment and is found in air, food and 
water. Cd ions are absorbed by most tissues of the body and become concentrated mainly in liver and 
kidney and it has a long biological half-life of 11 to 20 years in humans [161]. Cadmium is listed by 
the U.S. Environmental Protection Agency as one of 126 priority pollutants. The most dangerous 
characteristic of cadmium is that it accumulates throughout a lifetime. Chronic human exposure to Cd 
results in renal dysfunction, anemia, hepatic dysfunction, osteotoxicities, and cancer in multiple organs, 
potentially including the kidney [162,163]. Because of its carcinogenic properties, cadmium has been 
classified as a #1 category human carcinogen by the International Agency for Research on Cancer, 
Lyon, France [164]. Cadmium is a potent human carcinogen and has been associated with cancers of 
the lung, prostate, pancreas, and kidney. Cadmium can cause osteoporosis, anemia, non-hypertrophic 
emphysema, irreversible renal tubular injury, eosinophilia, anosmia and chronic rhinitis. Cd-induced 
nephrotoxicity is clearly the most important and the most frequently occurring ailment in humans as a 
result of chronic exposure to the metal [165]. The various toxic effects induced by cadmium and other 
heavy metals in biological systems might be due to alterations in the antioxidant defense system [166]. 
Cadmium-induced oxidative damage has been demonstrated by the increased lipid peroxidation and 
inhibition of enzymes required to prevent such oxidative damage [167]. It has been suggested that the Int. J. Environ. Res. Public Health 2010, 7                 
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mechanisms of acute Cd toxicity involve the depletion of glutathione and protein-bound sulfhydryl 
groups, resulting in enhanced production of ROS such as superoxide ion, hydrogen peroxide, and 
hydroxyl  radicals  [168,169].  ROS has been implicated in chronic  Cd nephrotoxicity  [170], 
immunotoxicity  [171], and carcinogenesis  [172]. Cd-induced inflammation in the liver is another 
important mechanism for Cd-induced oxidative stress [173]. Mitochondrion is an important target of 
Cd  toxicity  [174]. It has been proposed that Cd initially binds  to protein thiols in mitochondrial 
membrane, affects mitochondrial permeability transition, inhibits respiratory chain reaction, and then 
generates ROS  [175].  Cadmium  accumulation in the brain causes behavioral  alteration, which is 
exacerbated in rats fed with low protein diet [176]. Metallothionein (MT), a low-molecular-weight, 
cysteine-rich, metal-binding protein, has been  shown to play a protective role in Cd-induced 
hepatotoxicity and nephrotoxicity [177].  
Effective chelation therapy against cadmium has yet to be identified, but CaNa2EDTA has also been 
recommended with no proven clinical benefits. It is suggested that CaNa2EDTA at the dose of   
75 mg/kg/day in three to six divided doses for five days (total dose per five days not exceeding more 
than 500 mg/kg) may be prescribed immediately after Cd exposure. Since decrease in efficacy of 
cadmium therapy happens in parallel to distribution of metal in the tissue. CaNa3DTPA, an effective 
antidote against cobalt is also found effective against acute cadmium toxicity. However, it is less 
effective as compared to carbodithioates [27,28]. The usual widely accepted dose of CaNa3DTPA or 
ZnNa3DTPA is 1 gm/day in single dose, two to five days a week via im administration. Various 
analogues of carbodithioates including diethyl  (De), dimethyl  (Dm),  and diisopropyl  (Di)—
dithiocarbamates (DTC) have been investigated for their chelation efficacy against cadmium toxicity. 
The analogues although were effective but showed greater efficacy with delayed injection indicating 
interaction with Cd-thionein (bound Cd) rather than free ionic Cd. Further, combination therapy of 
DeDTC with DTPA caused excretion of increased concentrations of Cd in urine. It was suggested that 
DTPA acts directly with DeDTC in Cd complexation where DTPA contributes in increased urinary 
excretion of the complex by virtue of its polarity [167].  
 
7.3.5. Mercury 
 
Mercury is a naturally occurring constituent of the Earth’s crust and is found in several chemical 
and physical forms. In its elemental (metallic) form, it exists in a liquid state at room temperature and 
readily volatilizes at standard temperature (0 °C) and pressure (1 atm) to form mercury vapors. In 
recent years, elemental mercury has proven to be a potential source of toxicosis in children [178,179]. 
In the environment, humans and animals are exposed to numerous chemical forms of mercury, 
including elemental mercury vapor (Hg), inorganic mercurous [Hg (I)], mercuric [Hg (II)] and organic 
mercuric compounds. Elemental mercury can be released from dental amalgam restorations [180] and 
can then be converted into inorganic mercury in the body which can accumulate in the brain [181]. 
Metallic mercury vapor is both neurotoxicant and nephrotoxicant. Exposure to significant levels of 
metallic mercury can result in neurologic, respiratory, renal, reproductive, immunologic, dermatologic, 
and a variety of other effects [182]. Mercurous and mercuric ions impart their toxicological effects 
mainly through molecular interactions with sulfhydryl groups on various molecules like GSH, 
metallothionein (MT) and albumin [183-187]. Mercurials have been reported to cause apoptosis in Int. J. Environ. Res. Public Health 2010, 7                 
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cultured neurons;  however, the  signaling  pathways resulting in cell  death have not been well 
characterized. It has been reported that skeletal muscle is an important deposit of MeHg [188] and the 
activated antioxidant defense system of cells provides a compensatory mechanism for HgCl2 induced 
oxidative stress. However, such a phenomenon has not been reported in neurons [189] and hence Hg 
exhibits a more neurotoxic effect [106]. 
Dimercaprol and D-penicillamine has been the prescribed chelation agents against inorganic and 
elemental mercury poisoning. Recommended treatment include, dimercaprol at 5 mg/kg dose im for 
high level symptomatic patients and D-penicillamine at 250 mg/kg orally for asymptomatic patients or 
incase of low level exposure. Hydrophilic analogues of BAL, DMPS, and DMSA  have been 
successfully tested for treatment of toxicity by mercurial compounds [190]. DMPS has shown effective 
mobilization of mercury from kidney and reduced its biological half life [191]. DMPS is the drug of 
choice to reduce the burden of alkylmercury from the body including brain [191]. Further, DMPS is an 
approved drug in Germany for the treatment of mercury it has also been used for its provocative test. It 
is important to note that BAL may be contraindicated in organic mercury (phenyl- and alkylmercury) 
poisoning as the lipid soluble complex formed by it may increase mercury distribution into tissue and 
brain making it more detrimental.  
 
7.3.6. Iron 
 
Iron is an essential micronutrient utilized in almost every aspect of normal cell function and it is 
particularly crucial for the conservation of energy. Iron is a well known hepatotoxin. Iron overload is a 
less frequent condition, but a high content of tissue iron has been associated with several pathological 
conditions, including liver and heart diseases [193], cancer [194], neurodegenerative disorders [195], 
diabetes and immunological disorders [196]. Hepatic fibrosis and cirrhosis are the major outcomes of 
chronic iron overload as well as to repeated blood transfusion [197]. Iron toxicity is thus generally 
divided into five clinical stages, gastrointestinal toxicity, circulatory shock, relative stability, 
hepatotoxicity and gastrointestinal scarring. Iron toxicity is associated with primary hemochromatosis, 
high dietary iron intake and frequent blood transfusion. Oxidative stress is a general condition in 
hemodialysis patients [198], the periodic intravenous iron injection being a factor contributing to 
oxidative stress. The gastrointestinal tract is the primary target site, which occur without systemic 
toxicity. The chief site of systemic toxicity is the heart while liver is susceptible because, unlike other 
organs it is capable of clearing nontransferrin-bound iron [199]. Toxic shock is the most common 
cause of death in iron poisoning. At an early stage it is hypovolemic due to significant loss of blood 
and fluid from gastrointestinal tract. Hepatic necrosis is the next common cause of death. A serum 
concentration of more than 500 µg/dL is the recommended laboratory indicator. Common symptoms 
include vomiting within first 30 min to several hours, followed by abdominal pain, diarrhea,  
hyper-glycemia and fever. 
Treatment of iron poisoning involves decontamination of gastrointestinal, supportive care and the 
administration of a chelating agent. Deferoxamine is the specific and most potent chelator for iron and 
known for its high affinity for ferric form (Fe
3+)  but has a very low affinity for calcium (Ca
2+). 
Deferoxamine needs to be given either through the intramuscular (90 mg to 1 g/kg) or intravenously at 
a rate of 15 mg/kg/h. Its gastrointestinal absorption is very low. Irrespective of the route of Int. J. Environ. Res. Public Health 2010, 7                 
 
2774 
administration the daily dose should not exceed 6 g. Patients should be monitored carefully for 
gastrointestinal complications and shock after the treatment is over.  Oral Deferiprone   
(1,2-dimethyl-3-hydroxypyrid-4-one) has been shown to be as effective as s.c. desferrioxamine in the 
removal of iron in human and have a similar but different toxicity profile from desferrioxamine in both 
animals and humans [200]. There are few recent encouraging developments following the introduction 
deferiprone in combination with deferoxamine [201]. Variable doses of deferiprone (50–120 mg/kg) 
and deferoxamine (20–60 mg/kg) have been used to achieve low and safe body iron stores but the 
effects of these treatments are variables in patients. Various recent studies demonstrated the safety and 
efficacy of another new iron chelator, Deferasirox in reducing iron burden in iron-overloaded patients. 
Deferasirox, a tridentate oral chelator approved for the chronic iron overload offers a convenient, 
effective and promising alternative to deferoxamine [66]. This chelator is likely to be a significant 
development in the treatment of transfusional iron overload, due to its ability to provide constant 
chelation coverage and the potential to improve compliance [202]. 
 
8. Role of Antioxidants during Chelation  
 
Induction of reactive oxygen species by metals and subsequent depletion of antioxidant cell 
defenses can result in disruption of the pro-oxidant/antioxidant balance in tissues [203]. In the event 
that oxidative stress can be partially implicated in toxicity of metals, a therapeutic strategy to increase 
the antioxidant capacity of cells may fortify the long term effective treatment. This may be 
accomplished by either reducing the possibility of metal interacting with critical biomolecules and 
inducing oxidative damage, or by bolstering the cells antioxidant defenses through endogenous 
supplementation of antioxidant molecules. Although many investigators have confirmed metal induced 
oxidative stress, the usefulness of antioxidants along or in conjunction with chelation therapy has not 
been extensively investigated yet. Vitamins, essential metals or amino acid supplementation during 
chelation therapy has been found to be beneficial in increasing metal mobilization and providing 
recoveries in number of altered biochemical variables [204-206]. These antioxidants (vitamin C and E, 
α-lipoic acid etc.) when given either alone or in combination with a chelating agent proved to be 
effective in mobilizing metal from soft as well as hard tissue [203]. The important role of heavy metals 
in oxidative damage suggested a new mechanism for an old problem, whether metals are involved in 
the oxidative deterioration of biological macromolecules. Although several mechanisms have been 
proposed to explain the heavy metal induced toxicity, none of the mechanisms have been yet defined 
explicitly.  Indirect  in vivo  evidence of oxidative involvement in metal induced pathotoxicity was 
demonstrated by alleviation of oxidative stress in the erythrocytes after treatment with thiol containing 
proven antioxidants, N-acetylcysteine and a succimer in arsenic exposed rats [115]. In addition to the 
role of micronutrients in modifying metal toxicity, these nutritional components can also act as 
complimentary chelating agents (adjuvants) increasing the efficacy of a known chelator, or by   
acting independently. 
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9. Conclusions 
 
Metals on the one hand serve as essential components of the normal health physiology yet on the 
other hand, can cause serious toxic manifestations. Chelation therapy has been the mainstay treatment 
against metal toxicity. Chelation therapy complexes the metal and allows removal of excess or toxic 
metal from the system rendering it immediately nontoxic and reducing the late effects. Although a 
range of metal chelators are now available for toxic metal chelation, development of molecules that 
may be categorized anywhere close to an ideal chelator is far from reality. Most chelators have the 
disadvantages of numerous adverse effects, non-specific binding and administration inconvenience. In 
the world of increasing metal exposure although chelation therapy is an important tool in fighting 
metal storage disorders yet lack of larger clinical trials still offers controversy on its clinical 
therapeutic benefits. However, inspite of all the drawbacks it is important to understand the need for 
more specific and advanced chelation molecules to not only resolve the unanswered poisonings like 
cadmium toxicity but also to achieve complete clinical recovery in cases of other metal disorders. 
Further, newer therapeutic strategies should be investigated that may provide better therapeutic 
outcomes. Employing combination therapy with more than one chelating agent and or prescribing 
antioxidants or nutraceuticals may be more seriously considered as crucial recommendations of 
chelation therapy. 
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